Clinical Trial Update: First Line Therapy for High Risk Acute GVHD [Phase 2]

View source ↗

Summary

Phase 2 trial update on first-line therapy for high-risk acute graft-versus-host disease (aGVHD) in stem cell transplant patients. Completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: aGVHD, Stem Cell Transplant Complications | Phase 2 | Status: COMPLETED